Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Susanne Gray Warner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4329-7943; OpenAlex author ID A5053554017. Sources: OpenAlex.

Their work

Papers
26 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 4 papers · 2023: 3 papers · 2024: 4 papers · 2025: 3 papers · 2026: 4 papers

Papers 26

  1. Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid. Co-author DOI 10.1002/jso.70292↗
  2. A decade of pancreatoduodenectomy outcomes for pancreatic adenocarcinoma: 2014-2023 analysis of the N SQIP pancreatectomy PUF database: A decade of pancreatodu… Co-author DOI 10.1016/j.hpb.2026.01.016↗
  3. Surgical Resection for Borderline and Locally Advanced Pancreatic Adenocarcinoma. First author DOI 10.1016/j.soc.2025.02.001↗
  4. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Co-author DOI 10.6004/jnccn.2025.7097↗
  5. Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.27871↗
  6. Long-Term Reoperation Rates Following Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1177/00031348241304021↗
  7. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  8. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1002/jso.27837↗
  9. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection. Co-author DOI 10.1016/j.hpb.2023.09.010↗
  10. Quality of Life and Gastrointestinal Symptoms in Long-term Survivors of Pancreatic Cancer Following Pancreatoduodenectomy. Co-author DOI 10.1097/sla.0000000000006053↗
  11. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14875-5↗
  12. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Co-author DOI 10.1097/xcs.0000000000000704↗
  13. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  14. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenoc… Co-author DOI 10.1245/s10434-023-14138-3↗
  15. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-a… Co-author DOI 10.1016/j.omto.2021.12.022↗
  16. Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer. Last author DOI 10.1016/j.omto.2022.02.022↗
  17. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Co-author DOI 10.1038/s41417-021-00350-4↗
  18. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  19. Corrigendum to 'Patterns of care and treatment outcomes in patients age 80 or older with non-metastatic pancreatic cancer' [Journal of Geriatric Oncology 11 (4… Co-author DOI 10.1016/j.jgo.2020.11.005↗
  20. Preoperative imaging characteristics predict poor survival and inadequate resection for left-sided pancreatic adenocarcinoma: a multi-institutional analysis. Co-author DOI 10.1016/j.hpb.2019.12.012↗
  21. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.12.027↗
  22. Patterns of care and treatment outcomes in patients age 80 or older with non-metastatic pancreatic cancer. Co-author DOI 10.1016/j.jgo.2019.12.006↗
  23. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis. Co-author DOI 10.1002/cam4.2491↗
  24. The role of sequential radiation following adjuvant chemotherapy in resected pancreatic cancer. Co-author DOI 10.21037/jgo.2019.01.19↗
  25. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. Co-author DOI 10.1186/s12967-018-1483-x↗
  26. A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer. First author DOI 10.3390/biomedicines6040104↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cornelius A. Thiels · 14 shared papers, 2022–2026 · strength 2.98
  2. Mark Joseph Truty · 13 shared papers, 2022–2026 · strength 2.62
  3. Michael L. Kendrick · 11 shared papers, 2022–2026 · strength 2.19
  4. Sean Patrick Cleary · 10 shared papers, 2022–2026 · strength 1.92
  5. Travis Edward Grotz · 7 shared papers, 2022–2026 · strength 1.27
  6. Chi Zhang · 4 shared papers, 2024–2025 · strength 0.89
  7. Jennifer A. Yonkus · 5 shared papers, 2022–2025 · strength 0.85
  8. Andrea Zironda · 4 shared papers, 2024–2025 · strength 0.84
  9. Yuman Fong MD · 6 shared papers, 2018–2022 · strength 0.71
  10. Robert R. McWilliams · 4 shared papers, 2022–2025 · strength 0.70
  11. Omar J. Haque · 1 shared paper, 2026 · strength 0.63
  12. Yanghee Woo · 5 shared papers, 2018–2022 · strength 0.61
  13. Sang‐In Kim · 5 shared papers, 2018–2022 · strength 0.61
  14. Zhifang Zhang · 4 shared papers, 2020–2022 · strength 0.53
  15. Amro M. Abdelrahman · 3 shared papers, 2022–2025 · strength 0.51
  16. Roberto Alva‐Ruiz · 3 shared papers, 2022–2025 · strength 0.48
  17. Hallbera Gudmundsdottir · 2 shared papers, 2023 · strength 0.36
  18. F. Lee · 1 shared paper, 2026 · strength 0.36
  19. Jennifer L. Leiting · 2 shared papers, 2022–2025 · strength 0.32
  20. Daniel D. Von Hoff · 2 shared papers, 2020–2022 · strength 0.25
  21. William Dale · 2 shared papers, 2020–2021 · strength 0.24
  22. Zhi Ven Fong · 1 shared paper, 2026 · strength 0.24
  23. Po Hong Tan · 1 shared paper, 2026 · strength 0.24
  24. Nabil Wasif · 1 shared paper, 2026 · strength 0.24
  25. John Andrew Stauffer · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.